A model to study the prion-like neuron to neuron transmission of alpha-synuclein pathology. In a wild type model, stereotactically injected into the striatum with sonicated mouse preformed fibrils (mPFFs)

• Seeding and progressive spreading of alpha-synuclein pathology to several connected brain regions
• Loss of dopaminergic terminals and inflammation in pathology-rich regions

APP-London model for studying Alzheimer’s disease. Due to the wildtype BACE-cleavage site, a preferred model for testing anti-beta-secretase and anti-gamma-secretase associated approaches

• Expression of human APP[V717I] under control of the neuron-specific Thy-1 promoter
• Gently progressing AD phenotype

A model for studyin gAlzheimer’s Disease that develops similar charcteristics as the APP-London model but at an accelerated pace

• Expression of human APP[V717I]  and human PS1[A246E] under control of the neuron-specific Thy-1 promoter
• Faster progressing AD phenotype

Tauopathy model for studying  Frontotemperal dementia and Alzheimer’s disease. Additionally, this model has been extensively used to assess experimental treatments that are currently in clinical testing.

• Expression of human TAU[P301L] under control of the neuron-specific Thy-1 promotor
• A milder Tauopathy model with onset around 7 months
• More viariability in onset of Tau pathology, correlating with clasping score

Tauopathy model for Frontotemperal dementia and Alzheimer’s disease.

• Expression of human TAU[P301S] under control of the neuron-specific Thy-1 promotor
• An aggressive tau-o-pathy model with onset around as of 3-4 months of age
• Minor variability in the onset of progressive hyperphosphorylation and conformational change of Tau
• Less aggressive heterozygous TAU[P301S] alternative available as well, with onset around 9 months of age

A combined APP and Tau model for studying Alzheimer’s disease.

• Expression of human APP[V717I] and human TAU[P301S] (4R0N) under control of the neuron-specific Thy-1 promotor
• Combined and progressive β-amyloid and and Tau pathology with inflammation and cognitive impairment

A combined APP and Tau model for studying Alzheimer’s disease.

• Expression of human APP[V717I] and human TAU[P301S] (4R/2N) under control of the neuron-specific Thy-1 promotor
• Combined and progressive β-amyloid and and Tau pathology

A model to study the prion-like neuron to neuron trans-synaptic transmission of Tau pathology

• In the Tau[P301S] or TAU[P301L] model, injected with either brain lysate of each respective model or with synthetic fibrils
• Significant seeding and spreading of AT8-positive tangle-like inclusions in the ipsilateral and contralateral hippocampus